Filing Details
SANGAMO THERAPEUTICS, INC (NASDAQ:SGMO) filed a Form 8-K with the Securities and Exchange Commission on July 20, 2026, disclosing a material event.
8k filedNASDAQ:SGMO
SANGAMO THERAPEUTICS, INC (SGMO) Reports Material Event to SEC
Filing Details SANGAMO THERAPEUTICS, INC (NASDAQ:SGMO) filed a Form 8-K with the Securities and Exchange Commission on July 20, 2026, disclosing a material event. Market Context…
Market Context
SANGAMO THERAPEUTICS, INC's stock currently trades at $0.07 with a market capitalization of $154.1M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for SANGAMO THERAPEUTICS, INC's stock.
All SEC filings for SANGAMO THERAPEUTICS, INC are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SGMO Stock Page
Frequently Asked Questions
Where can I read SGMO's SEC filings?
Browse all filings on our SGMO SEC filings page.
What types of SEC filings does SANGAMO THERAPEUTICS, INC file?
Public companies like SANGAMO THERAPEUTICS, INC file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.